Special Interest Group (SIG) on Drug Delivery and Manufacturing (DDM)  
Annual Report 2020

• Prof. Erem Bilensoy (DDM SIG vice-chair) has submitted an article entitled “Printing Technologies in Drug Delivery and Manufacturing” to the BPS Newsletter.
• SIG on DDM collaborated with YPG on webinars as mentioned below that include COVID-19: "Introduction to FIP SIGs: Drug Delivery and Manufacturing, New Medicines, and New Generation of Pharmaceutical Scientists" "Medicine supply disruption and shortage during this pandemic" "Vaccines in development for COVID-19" Prof. Aliasger Salem (DDM SIG vice-chair) did a webinar of Introduction SIG on DDM to FIP member on Sunday July 12, 2020.
• Dr Tetsuya Ozeki (DDM SIG chair) and Prof. Bilensoy have contributed to the PSWC 2020 virtual as Ad Hoc programming Committee member and also as a chair of the session of B2 - Nanopharmaceuticals for precision drug delivery on Oct 6. Prof. Bilensoy has also done a presentation.
• Dr Ozeki was invited to accept the FIP YPG Mentoring Program Mentor-Mentee. The period is from September 1, 2020 to May 1, 2021. He submitted the month 1 mentoring plan in September and the month 3 report at the end of November.
• We have done the BPS special project "Current topics surrounding the formulation of medicine for children: The investigation and education for future pharmacists and researchers in Nagoya City University".
• SIG on DDM collaborated with Academy of Pharmaceutical Scientists (APS) on FIP Digital Event Plan (DEP), January 26, 2021. Dr Ozeki was a moderator for the event entitled “Manufacturing Classification System for oral solid dosage forms: Good in Theory and in Practice”.

SIG on DDM is proud of establishing a new FG:
• Pediatric Formulations Focus Group (PFFG) was been newly formed in DDM SIG. Dr Hala Fadda (Butler University, USA) is chair of the FG. The first zoom meeting was held with FIP Hospital and Community Pharmacy sections, DDM and Academy of Pharmaceutical Sciences and Technology Japan (APSTJ) on 5th Jan 2021, 12 pm CET. We discussed the purpose of this FG, future activities, and international relations.
The attendees were as follows:
• Representatives from International Pharmaceutical Federation (FIP)
  Paula Cohen, FIP Board Supporter and Coordinator
  Hala Fadda, Chair of PFFG
  Rob Moss - President FIP Hospital Pharmacy Section
  Tetsuya Ozeki – Chair of Drug Delivery Manufacturing SIG
  Lars-Åke Söderlund – President FIP Community Pharmacy Section
• Representatives from Academy of Pharmaceutical Science and Technology Japan (APSTJ)
  Tsutomu Harada – Pediatric Formulation Chair of APSTJ
  Takehisa Hanawa - Executive Committee of the Clinical Pharmaceutics FG of the APSTJ

Dr Maria Carvalho and Dr Régis Vaillancourt are the representatives from FIP community and hospital pharmacy sections, respectively, on our PFFG. Formulation science distinguishes our profession and at FIP we are working across the profession to identify and meet the pediatric oral formulations needs of different regions. Extemporaneous compounding continues to play an important role for pediatric oral preparations when commercial formulations are not available. Disparities in compounding practices remain, however, and a global, coordinated effort is needed to harmonize oral extemporaneous pediatric preparations. Our ultimate goal is to develop an open-access FIP formulary of standardized oral extemporaneous pediatric preparations.

Goals in 2021:

• Goal #1: The DDM leadership team will engage more effectively with colleagues from various BPP Sections in joint programming activities to underline invaluable relationship between clinical and practical outcomes and scientifically designed drug delivery and manufacturing.
• Goal #2: To disseminate knowledge and facilitate networking between drug delivery and manufacturing professionals worldwide through webinars, opinion papers or reports
• Goal #3: To launch a PFFG survey to identify compounding practices, challenges and needs of oral extemporaneous paediatric preparations.